$KRBP
Kiromic Biopharma, Inc.

2024 Q3 Form 10-Q Financial Statement

#000143774924025818 Filed on August 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.331M
YoY Change -3.49%
% of Gross Profit
Research & Development $4.228M $4.135M
YoY Change 57.93% 110.26%
% of Gross Profit
Depreciation & Amortization $552.0K $557.0K
YoY Change -1.45% 1.35%
% of Gross Profit
Operating Expenses $6.603M $6.353M
YoY Change 18.94% 48.0%
Operating Profit -$6.603M -$6.353M
YoY Change 18.94% 48.0%
Interest Expense -$957.0K
YoY Change 185.33%
% of Operating Profit
Other Income/Expense, Net -$832.0K -$472.0K
YoY Change -146.43% 28.79%
Pretax Income -$6.825M
YoY Change 0.9%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.435M -$6.825M
YoY Change 77.3% 0.9%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$5.54
COMMON SHARES
Basic Shares Outstanding 1.546M 1.288M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.048M
YoY Change 49.69%
Cash & Equivalents $2.924M $4.048M
Short-Term Investments
Other Short-Term Assets $1.979M
YoY Change -1.49%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.303M $6.027M
YoY Change -27.53% 27.87%
LONG-TERM ASSETS
Property, Plant & Equipment $4.847M $5.183M
YoY Change -26.36% -26.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $21.00K $21.00K
YoY Change -1.87% -1.87%
Total Long-Term Assets $5.942M $6.437M
YoY Change -28.37% -27.87%
TOTAL ASSETS
Total Short-Term Assets $4.303M $6.027M
Total Long-Term Assets $5.942M $6.437M
Total Assets $10.25M $12.46M
YoY Change -28.02% -8.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.693M $1.996M
YoY Change -60.14% -69.86%
Accrued Expenses $2.925M
YoY Change -23.34%
Deferred Revenue
YoY Change
Short-Term Debt $12.14M
YoY Change 5232.16%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.13M $17.06M
YoY Change 8.39% -8.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $577.0K
YoY Change -53.15%
Total Long-Term Liabilities $577.0K
YoY Change -53.15%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.13M $17.06M
Total Long-Term Liabilities $577.0K
Total Liabilities $19.53M $17.63M
YoY Change 4.34% -11.53%
SHAREHOLDERS EQUITY
Retained Earnings -$143.3M -$135.9M
YoY Change 21.23% 19.2%
Common Stock $1.000K $1.000K
YoY Change -14.97% -14.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$9.288M -$5.170M
YoY Change
Total Liabilities & Shareholders Equity $10.25M $12.46M
YoY Change -28.02% -8.6%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$7.435M -$6.825M
YoY Change 77.3% 0.9%
Depreciation, Depletion And Amortization $552.0K $557.0K
YoY Change -1.45% 1.35%
Cash From Operating Activities -$8.180M
YoY Change 26.61%
INVESTING ACTIVITIES
Capital Expenditures $98.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$98.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.781M
YoY Change 23.49%
NET CHANGE
Cash From Operating Activities -8.180M
Cash From Investing Activities -98.00K
Cash From Financing Activities 8.781M
Net Change In Cash 503.0K
YoY Change -22.6%
FREE CASH FLOW
Cash From Operating Activities -$8.180M
Capital Expenditures $98.00K
Free Cash Flow -$8.278M
YoY Change 28.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
30838
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
30838
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
14000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
14000
CY2024Q2 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
35364000 usd
CY2023Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
16206000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1542420
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1542420
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1258460
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1258460
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 usd
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 usd
CY2024Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0 usd
CY2024Q2 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 pure
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39619
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4762913
dei Entity Address Address Line1
EntityAddressAddressLine1
7707 Fannin Street, Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77054
dei City Area Code
CityAreaCode
832
dei Local Phone Number
LocalPhoneNumber
968-4888
dei Security12b Title
Security12bTitle
Common Shares, par value $0.001 per share
dei Trading Symbol
TradingSymbol
KRBP
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1545920
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4048000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3204000 usd
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
131000 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1848000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1226000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
6027000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4430000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5183000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6175000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1233000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1543000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
21000 usd
CY2024Q2 us-gaap Assets
Assets
12464000 usd
CY2023Q4 us-gaap Assets
Assets
12169000 usd
CY2024Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
12040000 usd
CY2023Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
14000000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1996000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2136000 usd
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1161000 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1673000 usd
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
1108000 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1938000 usd
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
96000 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
656000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
631000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17057000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20378000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
577000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
912000 usd
CY2024Q2 us-gaap Liabilities
Liabilities
17634000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
21290000 usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
130699000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
113775000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135870000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122897000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-5170000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-9121000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12464000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12169000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4135000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1967000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7157000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4042000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2218000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2326000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4309000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5028000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
6353000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4293000 usd
us-gaap Operating Expenses
OperatingExpenses
11466000 usd
us-gaap Operating Expenses
OperatingExpenses
9070000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6353000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4293000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11466000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9070000 usd
CY2024Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
957000 usd
CY2023Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
335000 usd
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2028000 usd
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
779000 usd
CY2024Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
-0 usd
CY2023Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
366000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
-0 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
445000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
485000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1770000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
521000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1770000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-472000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2471000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1507000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2994000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6825000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6764000 usd
us-gaap Net Income Loss
NetIncomeLoss
-12973000 usd
us-gaap Net Income Loss
NetIncomeLoss
-12064000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-9121000 usd
CY2024Q1 krbp Adjustments To Additional Paid In Capital Amortization Of Common Stock Discount
AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount
86000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
86000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
57000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-6148000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-7212000 usd
CY2024Q2 krbp Adjustments To Additional Paid In Capital Amortization Of Common Stock Discount
AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount
86000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
86000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6825000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-5170000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5775000 usd
CY2023Q1 krbp Adjustments To Additional Paid In Capital Amortization Of Common Stock Discount
AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount
85000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
85000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5300000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-8140000 usd
CY2023Q2 krbp Adjustments To Additional Paid In Capital Amortization Of Common Stock Discount
AdjustmentsToAdditionalPaidInCapitalAmortizationOfCommonStockDiscount
86000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
86000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
659000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
85000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
35000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6764000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6295000 usd
us-gaap Net Income Loss
NetIncomeLoss
-12973000 usd
us-gaap Net Income Loss
NetIncomeLoss
-12064000 usd
us-gaap Depreciation
Depreciation
1114000 usd
us-gaap Depreciation
Depreciation
1105000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
310000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
277000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
86000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
56000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
445000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
621000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
962000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-143000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1340000 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-830000 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
750000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-512000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1433000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-310000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-289000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13879000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10589000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
119000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-119000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
14877000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
12400000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
659000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
-0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
82000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
400000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
304000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
329000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14973000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12648000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations
975000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations
2059000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3204000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
645000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4179000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2704000 usd
us-gaap Interest Paid Net
InterestPaidNet
9000 usd
us-gaap Interest Paid Net
InterestPaidNet
35000 usd
krbp Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 usd
krbp Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
3000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
30000 usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 usd
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
620000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4048000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2704000 usd
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
131000 usd
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4179000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2704000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13900000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135900000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Use of Estimates</b>—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, warrants to purchase common stock underlying shares of Series B Preferred Stock and public offering common stock, and estimating services incurred by <em style="font: inherit;">third</em>-party service providers used to recognize research and development expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Concentrations of Credit Risk and Other Uncertainties</b>—Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances <em style="font: inherit;"> may </em>at times exceed federally insured limits. The Company has <em style="font: inherit;">not</em> incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is <em style="font: inherit;">not</em> exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of <em style="font: inherit;">third</em>-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p>
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
131000 usd
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2024Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-6825000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6764000 usd
us-gaap Net Income Loss
NetIncomeLoss
-12973000 usd
us-gaap Net Income Loss
NetIncomeLoss
-12064000 usd
CY2024Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1432000 usd
CY2023Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
515000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2321000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
515000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8343000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7365000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15466000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12750000 usd
CY2024Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
3136000 usd
CY2023Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
3126000 usd
CY2024Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
7372000 usd
CY2023Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
7372000 usd
CY2024Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
137000 usd
CY2023Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
137000 usd
CY2024Q2 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
402000 usd
CY2023Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
360000 usd
CY2024Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
171000 usd
CY2023Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
101000 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11218000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11096000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6035000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4921000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5183000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6175000 usd
CY2024Q2 us-gaap Depreciation
Depreciation
557000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
550000 usd
us-gaap Depreciation
Depreciation
1114000 usd
us-gaap Depreciation
Depreciation
1105000 usd
CY2024Q2 us-gaap Litigation Reserve Current
LitigationReserveCurrent
0 usd
CY2023Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
448000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
940000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
865000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
221000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
360000 usd
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1161000 usd
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1673000 usd
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
12040000 usd
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
14000000 usd
CY2024Q2 us-gaap Net Rentable Area
NetRentableArea
149000 acre
CY2024Q2 us-gaap Variable Lease Payment
VariableLeasePayment
0 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1233000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1543000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1233000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1543000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
656000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
631000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
577000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
912000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1233000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1543000 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
179000 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
180000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
358000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
358000 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M2D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M2D
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M2D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M2D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0712 pure
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0712 pure
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0712 pure
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0712 pure
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
359000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
725000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
242000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1326000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
93000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1233000 usd
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
60000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.25 pure
CY2024Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
1432000 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
2321000 usd
CY2024Q2 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
35364000 usd
CY2023Q2 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
16206000 usd
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure

Files In Submission

Name View Source Status
0001437749-24-025818-index-headers.html Edgar Link pending
0001437749-24-025818-index.html Edgar Link pending
0001437749-24-025818.txt Edgar Link pending
0001437749-24-025818-xbrl.zip Edgar Link pending
ex_681151.htm Edgar Link pending
ex_681152.htm Edgar Link pending
ex_681153.htm Edgar Link pending
ex_681154.htm Edgar Link pending
ex_710259.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
krbp-20240630.xsd Edgar Link pending
krbp20240630_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
krbp-20240630_cal.xml Edgar Link unprocessable
krbp-20240630_def.xml Edgar Link unprocessable
krbp-20240630_lab.xml Edgar Link unprocessable
krbp-20240630_pre.xml Edgar Link unprocessable
krbp20240630_10q_htm.xml Edgar Link completed
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable